PeerView Oncology
2020 Update on CDK4/6 Inhibitors in BC: FDA-Approved Practice Changing Palbociclib, Ribociclib & Abemaciclib - What Are the Differences in Dosing, ORR & AE?
In this activity, breast cancer experts Joyce O’Shaughnessy, MD, and Sara M. Tolaney, MD, MPH, ...
read more ↘
read more ↘
Comments 2
Login to view comments.
Click here to Login
